Vaxil Bio Ltd.
VXLLF
$0.10
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.17% | -13.03% | 73.05% | 154.87% | 35.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.17% | -13.03% | 20.00% | 200.44% | 31.30% |
| Operating Income | 28.17% | 13.03% | -20.00% | -200.44% | -31.30% |
| Income Before Tax | 45.08% | 184.69% | -13.49% | -182.20% | -26.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.08% | 184.69% | -13.49% | -182.20% | -26.32% |
| Earnings from Discontinued Operations | -- | 184.31% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.61% | 184.92% | -13.49% | -182.20% | -71.77% |
| EBIT | 28.17% | 13.03% | -20.00% | -200.44% | -31.30% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 59.54% | 184.73% | -13.38% | -181.43% | -72.37% |
| Normalized Basic EPS | 45.00% | 184.29% | -13.27% | -169.23% | -7.14% |
| EPS Diluted | 59.54% | 184.73% | -13.38% | -181.43% | -72.37% |
| Normalized Diluted EPS | 45.00% | 184.29% | -13.27% | -169.23% | -7.14% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |